SCF ENCYCLOPEDIA ENTRY

EARLY-ONSET ALZHEIMER’S DISEASE

SCF Registry Code: SCF-RDOS-NEURO-0002-EOAD

Disease Classification: Early-Onset Neurodegenerative Dementia

Parent Disease: ALZHEIMER’S DISEASE

Domain: Neurodegeneration • Neurogenetics • Neuroimmunology • Neuroenergetics • Connectomics • Precision Neurology

I. Definition

EARLY-ONSET ALZHEIMER’S DISEASE (EOAD) is a subtype of ALZHEIMER’S DISEASE characterized by symptom onset before 65 years of age, typically between ages 30–64 years. EOAD often exhibits a more aggressive clinical course, greater genetic contribution, faster progression, and increased involvement of non-memory cognitive domains compared with late-onset ALZHEIMER’S DISEASE.

Within the SCF framework, EOAD is classified as a Genetically Accelerated Neurodegenerative Convergence Syndrome involving premature failure of neural bioenergetic, proteostatic, connectomic, and neuroimmune systems.

II. Epidemiology

III. Etiopathogenic Core

Primary Disease Drivers

Familial EOAD

Strongly associated with autosomal dominant mutations:

Result:

• Accelerated amyloid accumulation
• Earlier neuronal dysfunction
• Increased synaptic degeneration

Sporadic EOAD

May involve combinations of:

• APOE ε4
• TREM2 variants
• Epigenetic dysregulation
• Mitochondrial dysfunction
• Environmental triggers

IV. SCF Fault Architecture

Using the SCF Pathophysiology Protocol, EOAD demonstrates accelerated collapse across multiple biological systems.

V. Molecular Multi-Omics Pathogenesis Map

Genomics

Primary drivers:

• APP
• PSEN1
• PSEN2
• APOE
• TREM2

Consequences:

• Increased amyloid burden
• Impaired protein clearance
• Neurodegenerative acceleration

Transcriptomics

Abnormal expression of:

• Synaptic maintenance genes
• Neuroplasticity regulators
• Inflammatory mediators

Result:

• Reduced adaptive capacity
• Premature network dysfunction

Epigenomics

Features:

• Accelerated epigenetic aging
• Methylation abnormalities
• Histone remodeling alterations

Result:

• Persistent pathogenic signaling

Proteomics

Major abnormalities:

• Amyloid-β deposition
• Hyperphosphorylated tau
• Synaptic protein depletion

Result:

• Earlier and more extensive neuronal injury

Metabolomics

Findings:

• Cerebral glucose hypometabolism
• ATP depletion
• Mitochondrial inefficiency

Result:

• Reduced neuronal resilience

Interactomics

Dysregulated pathways:

• PI3K/Akt
• mTOR
• NF-κB
• MAPK
• GSK3β

Result:

• Tau pathology amplification
• Cellular stress accumulation

Connectomics

Affected systems:

• Hippocampal circuits
• Fronto-parietal networks
• Executive control networks
• Default Mode Network

Result:

• Earlier executive dysfunction
• Language and visuospatial impairment

VI. Pathogenesis Flow (SCF Logic)

VII. Clinical Presentation

Memory-Dominant EOAD

Features:

• Episodic memory impairment
• Learning deficits
• Forgetfulness

Non-Amnestic EOAD

Common presentations:

Language-Predominant

• Word-finding difficulty
• Aphasia

Visuospatial-Predominant

• Spatial disorientation
• Visual processing deficits

Executive-Predominant

• Planning impairment
• Decision-making dysfunction
• Cognitive rigidity

VIII. Diagnostic Framework

Clinical Assessment

• Detailed neurological examination
• Neuropsychological testing
• Functional assessment

Biomarker Evaluation

Cerebrospinal Fluid

• Reduced Aβ42
• Elevated total tau
• Elevated phospho-tau

Blood Biomarkers

• pTau217
• pTau181
• Neurofilament Light Chain

Neuroimaging

MRI

Findings:

• Hippocampal atrophy
• Cortical thinning
• Posterior cortical involvement

PET Imaging

• Amyloid PET positivity
• Tau PET positivity
• FDG-PET hypometabolism

Genetic Testing

Recommended when:

• Onset before 60 years
• Strong family history
• Multigenerational disease pattern

Genes:

• APP
• PSEN1
• PSEN2

IX. SCF Disease Tier Classification

X. SCF Therapeutic Mechanisms

SCF-PCR Preventative

Objectives:

• Delay amyloid formation
• Preserve mitochondrial function
• Maintain neurovascular integrity

SCF-PCR Curative

Objectives:

• Reduce amyloid burden
• Decrease tau pathology
• Suppress neuroinflammation

SCF-PCR Restorative

Objectives:

• Restore synaptic function
• Enhance neuroplasticity
• Reconstruct connectomic integrity

XI. SCF Therapeutic Reconstruction Blueprint

XII. PROJECT RHENOVA — Integration Pathways

Neurogenetic Axis

Focus:

• APP
• PSEN1
• PSEN2

Neuroimmune Axis

Focus:

• TREM2
• Microglial regulation
• Cytokine modulation

Neuroenergetic Axis

Focus:

• Mitochondrial restoration
• ATP homeostasis

Connectomic Axis

Focus:

• Network preservation
• Synaptic integrity

Regenerative Axis

Focus:

• Neuroplasticity
• Neurotrophic signaling

XIII. Next Strategic Research Pathways

Pathway 1

Genotype-specific EOAD disease modeling.

Pathway 2

APP–PSEN precision therapeutic platforms.

Pathway 3

Tau propagation interruption technologies.

Pathway 4

Mitochondrial restoration and neuroenergetic rescue.

Pathway 5

Connectomic reconstruction and neural network recovery.

Pathway 6

Multi-omic biomarker-guided precision intervention.

Pathway 7

SCF-engineered therapeutic combinations optimized through TSSM, HSV-F², SV-EQ, MGIS, and SPCI synergy evaluation frameworks.

SCF ENCYCLOPEDIA SUMMARY

EARLY-ONSET ALZHEIMER’S DISEASE is a genetically enriched, aggressive subtype of ALZHEIMER’S DISEASE characterized by premature neurodegeneration driven by amyloid dysregulation, tau pathology, mitochondrial dysfunction, neuroimmune activation, and connectomic failure. Within the SCF framework, EOAD represents a high-priority neurodegenerative convergence syndrome requiring integrated Preventative–Curative–Restorative therapeutic reconstruction strategies focused on neurogenetic correction, bioenergetic restoration, neuroimmune regulation, and neural network preservation.

MASTER REGISTRY INDEX

SCF-RDOS-NEURO-0002-EOAD — EARLY-ONSET ALZHEIMER’S DISEASE

SCF-ENC-EOAD-0001 — SCF Encyclopedia Entry: EARLY-ONSET ALZHEIMER’S DISEASE

SCF-PATH-EXT-0001 — SCF Pathophysiology Protocol (Extended Version)

SCF-SCP-0001 — Synergistic Compatibility Principles

SCF-SEF-MD-0001 — SCF Synergistic Evaluation Framework

SCF-RHENOVA-EOAD-0001 — EARLY-ONSET ALZHEIMER’S DISEASE Therapeutic Reconstruction Program

SCF-RDOS-NEURO-MASTER-0001 — Neuroscience Disease, Disorder & Condition Master Registry